Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study.
COVID-19
RNAemia
SARS-CoV-2
mortality
viremia
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
21
09
2021
revised:
06
11
2021
accepted:
10
11
2021
pubmed:
14
12
2021
medline:
16
2
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
SARS-CoV-2 viremia at admission is associated with high risk for mortality. However, longitudinal data on viremia duration are limited. Viremic patients hospitalized for COVID-19 were included in a cohort. Time to serum viral clearance and the effect of viremia duration on the odds of mortality were calculated. One hundred and twenty-one viremic patients were included. Median age was 62 (IQR 52-71) years and 68% were males. The total in-hospital mortality of the cohort was 33%. Median time from admission to serum viral clearance was 7 (95% CI 6-8) days. Duration of viremia showed a relative risk ratio of 1.40 (95% CI 1.02-1.92) for the odds of mortality in an adjusted multinomial logistic regression. Serum viral clearance coincided with defervescence and decreasing C-reactive protein. Median time to serum viral clearance was 7 days after admission. The odds of mortality increased with 40% for each additional day of viremia.
Identifiants
pubmed: 34896666
pii: S0732-8893(21)00286-8
doi: 10.1016/j.diagmicrobio.2021.115595
pmc: PMC8595972
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115595Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
BMC Infect Dis. 2021 Feb 17;21(1):184
pubmed: 33596855
Br J Haematol. 2020 Jul;190(2):185-188
pubmed: 32557623
Clin Infect Dis. 2021 Aug 2;73(3):e799-e802
pubmed: 32888003
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Lancet Microbe. 2020 Oct;1(6):e245-e253
pubmed: 32844161
Clin Infect Dis. 2021 May 4;72(9):e291-e295
pubmed: 32965474
Ann Intensive Care. 2020 Dec 10;10(1):167
pubmed: 33301059
Clin Infect Dis. 2021 Nov 2;73(9):e2898-e2900
pubmed: 32898242
Clin Infect Dis. 2022 May 3;74(9):1525-1533
pubmed: 34374761
Braz J Infect Dis. 2020 Nov - Dec;24(6):565-569
pubmed: 32950458
J Infect. 2020 Dec;81(6):847-856
pubmed: 33049331
J Clin Virol. 2020 Dec;133:104655
pubmed: 33069846
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Crit Care. 2020 Dec 14;24(1):691
pubmed: 33317616
Clin Infect Dis. 2021 Nov 2;73(9):e2995-e3001
pubmed: 32856036
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34196300
Lancet Respir Med. 2020 Sep;8(9):e70
pubmed: 32771081
Nat Commun. 2020 Oct 30;11(1):5493
pubmed: 33127906
Intensive Care Med. 2020 Nov;46(11):2035-2047
pubmed: 33034689
mSphere. 2021 Jun 30;6(3):e0031121
pubmed: 34047654
Clin Infect Dis. 2022 Jan 29;74(2):218-226
pubmed: 33949665
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
J Infect Chemother. 2020 Nov;26(11):1220-1223
pubmed: 32792249
Clin Infect Dis. 2021 Nov 2;73(9):e2890-e2897
pubmed: 32803231
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440